cosmos health inc - COSM

COSM

Close Chg Chg %
0.44 0.01 2.23%

Closed Market

0.45

+0.01 (2.23%)

Volume: 832.32K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Company Overview: cosmos health inc - COSM

COSM Key Data

Open

$0.44

Day Range

0.42 - 0.47

52 Week Range

0.28 - 1.32

Market Cap

$17.59M

Shares Outstanding

37.43M

Public Float

24.41M

Beta

4.47

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.71

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.36M

 

COSM Performance

1 Week
 
-6.43%
 
1 Month
 
-18.26%
 
3 Months
 
-34.86%
 
1 Year
 
-35.79%
 
5 Years
 
-99.45%
 

COSM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About cosmos health inc - COSM

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

COSM At a Glance

Cosmos Health, Inc.
5 Agiou Georgiou Street
Thessaloniki, Central Macedonia 554 38
Phone 30-312-865-0026 Revenue 54.43M
Industry Pharmaceuticals: Major Net Income -16,183,018.00
Sector Health Technology 2024 Sales Growth 1.966%
Fiscal Year-end 12 / 2025 Employees 149
View SEC Filings

COSM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.235
Price to Book Ratio 0.644
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.735
Enterprise Value to Sales 0.446
Total Debt to Enterprise Value 0.487

COSM Efficiency

Revenue/Employee 365,277.866
Income Per Employee -108,610.859
Receivables Turnover 3.316
Total Asset Turnover 0.903

COSM Liquidity

Current Ratio 0.989
Quick Ratio 0.819
Cash Ratio 0.013

COSM Profitability

Gross Margin 5.626
Operating Margin -28.025
Pretax Margin -29.734
Net Margin -29.734
Return on Assets -26.836
Return on Equity -53.43
Return on Total Capital -44.516
Return on Invested Capital -48.653

COSM Capital Structure

Total Debt to Total Equity 48.183
Total Debt to Total Capital 32.516
Total Debt to Total Assets 21.764
Long-Term Debt to Equity 8.406
Long-Term Debt to Total Capital 5.673
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cosmos Health Inc - COSM

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
56.24M 50.35M 53.38M 54.43M
Sales Growth
+1.50% -10.48% +6.02% +1.97%
Cost of Goods Sold (COGS) incl D&A
48.36M 44.58M 49.64M 51.36M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
449.69K 188.89K 614.38K 1.25M
Depreciation
416.61K 155.81K 376.73K 416.92K
Amortization of Intangibles
33.09K 33.09K 239.84K 832.32K
COGS Growth
+1.29% -7.82% +11.36% +3.47%
Gross Income
7.88M 5.77M 3.74M 3.06M
Gross Income Growth
+2.85% -26.81% -35.24% -18.02%
Gross Profit Margin
+14.01% +11.46% +7.00% +5.63%
2021 2022 2023 2024 5-year trend
SG&A Expense
12.41M 13.24M 25.57M 18.31M
Research & Development
- - - 533.29K
-
Other SG&A
12.41M 13.24M 25.57M 17.78M
SGA Growth
+150.87% +6.67% +93.07% -28.36%
Other Operating Expense
- - - -
-
Unusual Expense
(802.72K) (985.54K) (3.36M) 289.51K
EBIT after Unusual Expense
(3.73M) (6.49M) (18.47M) (15.54M)
Non Operating Income/Expense
(536.09K) (2.60M) 795.86K 371.66K
Non-Operating Interest Income
46.32K 236.35K 662.86K 406.45K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.58M 3.97M 866.48K 1.01M
Interest Expense Growth
+28.11% +10.73% -78.15% +16.83%
Gross Interest Expense
3.58M 3.97M 866.48K 1.01M
Interest Capitalized
- - - -
-
Pretax Income
(7.85M) (13.06M) (18.54M) (16.18M)
Pretax Income Growth
-754.89% -66.36% -42.03% +12.73%
Pretax Margin
-13.95% -25.93% -34.74% -29.73%
Income Tax
- - 114.01K 775.05K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - 802.36K (75.72K)
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - (688.35K) 850.77K
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(7.96M) (13.83M) (18.54M) (16.18M)
Minority Interest Expense
- - - -
-
Net Income
(7.96M) (13.83M) (18.54M) (16.18M)
Net Income Growth
-1,070.00% -73.71% -34.07% +12.73%
Net Margin Growth
-14.16% -27.47% -34.74% -29.73%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(7.96M) (13.83M) (18.54M) (16.18M)
Preferred Dividends
7.63M 50.11M 7.24M 6.20M
Net Income Available to Common
(15.59M) (63.95M) (25.78M) (22.38M)
EPS (Basic)
-23.7385 -33.1637 -2.1543 -1.1687
EPS (Basic) Growth
-1,635.28% -39.70% +93.50% +45.75%
Basic Shares Outstanding
656.93K 1.93M 11.97M 19.15M
EPS (Diluted)
-23.7385 -33.1637 -2.1543 -1.1687
EPS (Diluted) Growth
-1,639.46% -39.70% +93.50% +45.75%
Diluted Shares Outstanding
656.93K 1.93M 11.97M 19.15M
EBITDA
(4.08M) (7.29M) (21.22M) (14.00M)
EBITDA Growth
-231.23% -78.40% -191.23% +34.00%
EBITDA Margin
-7.26% -14.47% -39.75% -25.73%

Snapshot

Average Recommendation BUY Average Target Price 3.00
Number of Ratings 1 Current Quarters Estimate -0.07
FY Report Date 03 / 2026 Current Year's Estimate -0.11
Last Quarter’s Earnings -0.04 Median PE on CY Estimate N/A
Year Ago Earnings -0.34 Next Fiscal Year Estimate 0.07
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -0.07 -0.03 -0.11 0.07
High Estimates -0.07 -0.03 -0.11 0.07
Low Estimate -0.07 -0.03 -0.11 0.07
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Cosmos Health Inc - COSM

Date Name Shares Transaction Value
Jan 27, 2026 Grigorios Siokas Chief Executive Officer; Director 8,182,120 Open market or private purchase of non-derivative security Non-derivative transaction at $0.5 per share 4,091,060.00
Feb 17, 2025 Anastasios H. Aslidis Director 40,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 17, 2025 John James Hoidas Director 20,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 17, 2025 John James Hoidas Director 15,000 Open market or private sale of non-derivative or derivative security 0.00
Feb 17, 2025 Manfred Ziegler Director 20,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 17, 2025 George Terzis Chief Financial Officer 727,263 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 17, 2025 Niko Bardakis Chief Operating Officer 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 17, 2025 Suhel Bhutawala Director 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cosmos Health Inc in the News